Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy
Journal for ImmunoTherapy of Cancer · 2025-05 · 13 (5) · e011074
DOI: 10.1136/jitc-2024-011074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.05.2025. Verfasst von Lisa K Poppe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Histone Deacetylase Inhibitors, Cytokines, Papillomavirus Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI Cooperative Research and Development Agreement (CRADA) with PDS Biotechnology, Intramural Research Program, National Cancer Institute.
Abstract (Originalsprache)
Background
Human papillomavirus (HPV)-associated malignancies continue to present a major health concern despite the development of prophylactic vaccines. Standard therapies offer limited benefit to patients with advanced-stage disease. Despite improved outcomes with programmed cell death protein-1 (PD-1) targeted therapies, treatment resistance and modest response rates highlight a significant unmet need to develop novel therapies for these patients. PDS0101 (designated HPV vaccine) is a liposomal nanoparticle HPV16-specific therapeutic vaccine that has been shown to generate strong HPV-specific responses in preclinical and clinical studies. Here we assess the efficacy of this HPV vaccine in combination with the tumor-targeting immunocytokine NHS-IL12 (PDS01ADC), plus either αPD-1 or the class I histone deacetylase inhibitor Entinostat.
Methods
Mice bearing HPV16 + , αPD-1 refractory TC-1 and mEER tumors were treated with HPV vaccine, NHS-IL12, and either αPD-1 or Entinostat to determine antitumor efficacy and survival benefits. A comprehensive analysis of the tumor microenvironment was performed using flow cytometry, multiplex immunofluorescence, chemokine and cytokine assessment, and single-cell RNA sequencing with T-cell receptor (TCR) enrichment.
Results
Combination of HPV vaccine and NHS-IL12 with either Entinostat or αPD-1 yielded significant antitumor activity and prolonged survival in αPD-1 refractory models of HPV16 + cancer, with superior activity employing Entinostat versus αPD-1 combination. Entinostat triple therapy increased overall and HPV16-specific tumor CD8 + T-cell infiltration with heightened cytotoxicity. TCR sequencing revealed a CD8 + T-cell clone unique to vaccine-treated cohorts, which displayed an enriched cytotoxic transcriptional profile with triple therapy. These effects were paralleled by strong differentiation of tumor-associated macrophages (TAMs) towards pro-inflammatory, antitumor M1-like cell states. Single-cell transcriptomic analysis indicated all three agents were required for highest modulation of both CD8 + T cells and TAMs conducive to tumor control. A biomarker signature reflecting the preclinical findings was found to be associated with improved survival in patients with HPV-associated malignancies.
Conclusion
Together, these findings provide a rationale for the combination of HPV vaccine, NHS-IL12, and Entinostat in the clinical setting for patients with HPV16-associated malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA schlomj@mail.nih.gov.
Förderung
- NCI Cooperative Research and Development Agreement (CRADA) with PDS Biotechnology
- Intramural Research Program, National Cancer Institute
Zitieren
APA
Poppe, L. K., Roller, N., Medina-Enriquez, M. M., Lassoued, W., Burnett, D., Lothstein, K. E., Khelifa, A. S., Miyamoto, M., Gulley, J. L., Jochems, C., Schlom, J., & Gameiro, S. R. (2025). Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy. Journal for ImmunoTherapy of Cancer, 13(5), e011074. https://doi.org/10.1136/jitc-2024-011074
Vancouver
Poppe LK, Roller N, Medina-Enriquez MM, Lassoued W, Burnett D, Lothstein KE, et al. Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy. Journal for ImmunoTherapy of Cancer. 2025;13(5):e011074. doi:10.1136/jitc-2024-011074
BibTeX
@article{Poppe2025,
author = {Poppe, Lisa K and Roller, Nicholas and Medina-Enriquez, Miriam Marlene and Lassoued, Wiem and Burnett, Daniel and Lothstein, Katherine E and Khelifa, Asma S and Miyamoto, Masaya and Gulley, James L and Jochems, Caroline and Schlom, Jeffrey and Gameiro, Sofia R},
title = {Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {5},
pages = {e011074},
doi = {10.1136/jitc-2024-011074}
}
EUVIMED